Почетна › Рак бубрега (карцином бубрежних ћелија) › Тексас › Houston
Kliničke studije za Рак бубрега (карцином бубрежних ћелија) u gradu Houston, TX
34 studija za Рак бубрега (карцином бубрежних ћелија) traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Тражи се учесникФаза 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- UT MD Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Тражи се учесникФаза 1
- NEO-811 Houston Site, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Тражи се учесникФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- Houston Methodist Hospital, Houston
- и још 2
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Тражи се учесникФаза 2
- UT MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Тражи се учесникФаза 1
- UT MD Anderson, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Тражи се учесникФаза 1
- Md Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Тражи се учесникФаза 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- и још 1
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Тражи се учесникФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Research Site, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Тражи се учесникФаза 1/2
- University of Texas - MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Houston Methodist Hospital, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Тражи се учесникФаза 1
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
Тражи се учесникОпсервациона студија
- The University of Texas MD Anderson Cancer Center, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Тражи се учесник
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Тражи се учесникФаза 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Studije za Рак бубрега (карцином бубрежних ћелија) u drugim gradovima
- New York City, NY29 студија
- St. Louis, MO25 студија
- Dallas, TX24 студија
- Nashville, TN24 студија
- Los Angeles, CA22 студија
- Boston, MA16 студија
- Philadelphia, PA16 студија
- Queens, NY16 студија
- Pittsburgh, PA15 студија
- Baldwin Park, CA15 студија
- Edison, NJ14 студија
- Rochester, MN14 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Рак јајника90 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.